UroGen Pharma Stock (NASDAQ:URGN)
Previous Close
$12.20
52W Range
$10.60 - $20.70
50D Avg
$12.95
200D Avg
$14.84
Market Cap
$502.42M
Avg Vol (3M)
$596.38K
Beta
1.12
Div Yield
-
URGN Company Profile
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
URGN Performance
Peer Comparison
Ticker | Company |
---|---|
VIGL | Vigil Neuroscience, Inc. |
SRRK | Scholar Rock Holding Corporation |
PRTC | PureTech Health plc |
IKNA | Ikena Oncology, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
ERAS | Erasca, Inc. |
INBX | Inhibrx Biosciences, Inc. |
GBIO | Generation Bio Co. |
VACC | Barinthus Biotherapeutics plc |
TYRA | Tyra Biosciences, Inc. |
KRON | Kronos Bio, Inc. |
CNTB | Connect Biopharma Holdings Limited |
CCCC | C4 Therapeutics, Inc. |
PEPG | PepGen Inc. |
XLO | Xilio Therapeutics, Inc. |
TARA | Protara Therapeutics, Inc. |
OVID | Ovid Therapeutics Inc. |
CELC | Celcuity Inc. |
MACK | Merrimack Pharmaceuticals, Inc. |
ELVN | Enliven Therapeutics, Inc. |
CMPX | Compass Therapeutics, Inc. |
ELYM | Eliem Therapeutics, Inc. |